A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02567656
Contact: Auris Huen, MD 713 745- 1113 email@example.com
Contact: Yasuhiro Oki, MD 713 792- 2860 yoki@@mdanderson.org
Sponsors and Collaborators
Rhizen Pharmaceuticals SA
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Carol Wilson, R.N., B.S. 713-563-4655 firstname.lastname@example.org
Contact: Alda Ashu, BSN, RN, OCN 713-563-3559 email@example.com